Innate Pharma
ISIN: FR0010331421 | Ticker: IPH | LEI: 9695002Y8420ZB8HJE29
Country: France
Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
Innate is a pioneer in the understanding of natural killer cell (NK cell) biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.
1999
Served areaWorldwide
Headcount215
Headquarters117 Avenue de Luminy, 13009 Marseille – France
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 307,423,000.00 | 267,496,000.00 | 207,863,000.00 |
| Noncurrent Assets | N/A | 133,972,000.00 | 129,241,000.00 | 68,033,000.00 |
| Property Plant And Equipment | N/A | 11,694,000.00 | 10,174,000.00 | 8,542,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 46,289,000.00 | 44,192,000.00 | 1,556,000.00 |
| Noncurrent Receivables | N/A | 29,821,000.00 | 29,821,000.00 | 14,099,000.00 |
| Deferred Tax Assets | N/A | 7,087,000.00 | 5,028,000.00 | 8,568,000.00 |
| Other Noncurrent Nonfinancial Assets | N/A | 147,000.00 | 148,000.00 | 149,000.00 |
| Current Assets | N/A | 173,451,000.00 | 138,256,000.00 | 139,831,000.00 |
| Trade And Other Current Receivables | N/A | 21,814,000.00 | 18,420,000.00 | 38,346,000.00 |
| Cash and cash equivalents | 202,887,000.00 | 136,792,000.00 | 103,756,000.00 | 84,225,000.00 |
| Equity And Liabilities | N/A | 307,423,000.00 | 267,496,000.00 | 207,863,000.00 |
| Equity | 217,416,000.00 | 155,976,000.00 | 107,440,000.00 | 54,151,000.00 |
| Issued Capital | N/A | 3,950,000.00 | 3,978,000.00 | 4,011,000.00 |
| Share Premium | N/A | 372,131,000.00 | 375,220,000.00 | 379,637,000.00 |
| Other Reserves | N/A | 355,000.00 | 456,000.00 | 819,000.00 |
| Noncurrent Liabilities | N/A | 105,959,000.00 | 80,169,000.00 | 112,374,000.00 |
| Noncurrent Provisions | N/A | 221,000.00 | 253,000.00 | 198,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | 4,177,000.00 | 2,975,000.00 | 2,550,000.00 |
| Noncurrent Contract Liabilities | N/A | N/A | 25,413,000.00 | 7,921,000.00 |
| Deferred Tax Liabilities | N/A | 7,087,000.00 | 5,028,000.00 | 8,568,000.00 |
| Current Liabilities | N/A | 45,488,000.00 | 79,886,000.00 | 41,338,000.00 |
| Current Provisions | N/A | 676,000.00 | 647,000.00 | 1,542,000.00 |
| Trade And Other Current Payables | N/A | 29,539,000.00 | 28,573,000.00 | 20,911,000.00 |
| Current Contract Liabilities | N/A | N/A | 12,500,000.00 | 6,560,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 69,773,000.00 | 24,703,000.00 | 57,674,000.00 |
| Revenue From Sale Of Goods | N/A | 0.00 | 59,000.00 |
| Revenue From Contracts With Customers | 56,155,000.00 | 12,112,000.00 | 49,580,000.00 |
| Profit Loss From Operating Activities | 1,079,000.00 | -47,825,000.00 | -57,425,000.00 |
| Finance Income | 4,855,000.00 | 6,344,000.00 | 4,775,000.00 |
| Finance Costs | 6,763,000.00 | 3,997,000.00 | 5,321,000.00 |
| Profit Loss Before Tax | -829,000.00 | -45,478,000.00 | -57,972,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 0.00 | 0.00 |
| Profit Loss From Continuing Operations | -829,000.00 | -45,478,000.00 | -57,972,000.00 |
| Profit Loss From Discontinued Operations | -63,155,000.00 | -7,331,000.00 | -131,000.00 |
| Profit (loss) | -63,984,000.00 | -52,809,000.00 | -58,103,000.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -63,984,000.00 | -52,809,000.00 | -58,103,000.00 |
| Adjustments For Finance Costs | N/A | 341,000.00 | 312,000.00 | 0.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 56,797,000.00 | 4,596,000.00 | 45,405,000.00 |
| Adjustments For Provisions | N/A | 604,000.00 | 4,000.00 | 839,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | 1,256,000.00 | -1,136,000.00 | -912,000.00 |
| Adjustments For Sharebased Payments | N/A | 2,475,000.00 | 2,617,000.00 | 4,249,000.00 |
| Adjustments For Fair Value Gains Losses | N/A | 577,000.00 | -987,000.00 | 1,372,000.00 |
| Other Adjustments To Reconcile Profit Loss | N/A | -254,000.00 | -1,185,000.00 | 15,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -51,767,000.00 | -58,457,000.00 | -19,154,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 9,000.00 | 7,000.00 | 0.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 907,000.00 | 929,000.00 | 535,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 10,375,000.00 | 401,000.00 | 587,000.00 |
| Proceeds From Other Longterm Assets Classified As Investing Activities | N/A | 0.00 | 40,000.00 | 0.00 |
| Purchase Of Other Longterm Assets Classified As Investing Activities | N/A | 59,000.00 | 1,000.00 | 1,000.00 |
| Interest Received Classified As Investing Activities | N/A | 962,000.00 | 367,000.00 | 0.00 |
| Cash Flows From Used In Investing Activities | N/A | -13,370,000.00 | -917,000.00 | 1,877,000.00 |
| Proceeds From Issuing Shares | N/A | 48,000.00 | 499,000.00 | 198,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 1,360,000.00 | 28,700,000.00 | 0.00 |
| Interest Paid Classified As Financing Activities | N/A | 341,000.00 | 312,000.00 | 0.00 |
| Cash Flows From Used In Financing Activities | N/A | -1,177,000.00 | 26,818,000.00 | -1,828,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 219,000.00 | -483,000.00 | -428,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | -66,096,000.00 | -33,037,000.00 | -19,531,000.00 |
| Cash and cash equivalents | 202,887,000.00 | 136,792,000.00 | 103,756,000.00 | 84,225,000.00 |
Please note that some sums might not add up.
FR0010331421
LEI9695002Y8420ZB8HJE29
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.